Cellectis S.A. (NASDAQ:CLLS) Receives $6.33 Average Target Price from Analysts

Cellectis S.A. (NASDAQ:CLLS) has earned an average recommendation of “Moderate Buy” from the five research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $6.3333.

CLLS has been the topic of a number of analyst reports. Jefferies Financial Group initiated coverage on shares of Cellectis in a research note on Tuesday, February 17th. They issued a “buy” rating and a $7.00 target price on the stock. Clear Str raised shares of Cellectis to a “strong-buy” rating in a research note on Tuesday, December 23rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellectis in a research note on Wednesday, January 21st.

Hedge Funds Weigh In On Cellectis

A number of large investors have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Cellectis by 228.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock worth $5,856,000 after purchasing an additional 3,284,409 shares in the last quarter. B Group Inc. lifted its holdings in Cellectis by 0.8% in the third quarter. B Group Inc. now owns 3,281,501 shares of the biotechnology company’s stock valued at $9,352,000 after buying an additional 25,000 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Cellectis in the fourth quarter valued at approximately $15,385,000. Citadel Advisors LLC acquired a new position in Cellectis in the third quarter valued at approximately $633,000. Finally, Marshall Wace LLP lifted its holdings in Cellectis by 1,610.3% in the fourth quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock valued at $864,000 after buying an additional 168,038 shares during the period. 63.90% of the stock is currently owned by institutional investors and hedge funds.

Cellectis Stock Performance

NASDAQ:CLLS opened at $3.59 on Wednesday. The firm’s 50-day moving average is $3.60 and its 200-day moving average is $3.96. Cellectis has a 52-week low of $1.32 and a 52-week high of $5.48. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.62 and a current ratio of 1.62. The company has a market cap of $360.22 million, a price-to-earnings ratio of -5.36 and a beta of 2.91.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings data on Thursday, March 19th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.16). Cellectis had a negative return on equity of 69.38% and a negative net margin of 84.92%.The company had revenue of $15.50 million for the quarter, compared to the consensus estimate of $10.74 million. Equities research analysts anticipate that Cellectis will post -0.46 earnings per share for the current year.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.